Home/Pipeline/OX-4224

OX-4224

Non-Small Cell Lung Cancer (NSCLC)

Phase 2Active

Key Facts

Indication

Non-Small Cell Lung Cancer (NSCLC)

Phase

Phase 2

Status

Active

Company

OmRx Oncology

About OmRx Oncology

OmRx Oncology is a private, pre-revenue biotech founded in 2019 with a mission to democratize access to cancer immunotherapy through oral small molecule checkpoint inhibitors. Its core strategy involves in-licensing and developing Phase 2-ready asset OX-4224, acquired from Gilead Sciences, targeting both underserved markets and advanced combination regimens in developed regions. The company aims to address significant unmet needs in global oncology by offering a lower-cost, orally administered alternative to intravenous antibody therapies, with a focus on improving accessibility and safety.

View full company profile

Therapeutic Areas

Oncology

Other Non-Small Cell Lung Cancer (NSCLC) Drugs

Drug	Company	Phase	Status
LW-02 Immunopheresis	Immunicom	Phase 2	Active
Idylla EGFR Mutation Assay	Biocartis	Approved	CE-IVD
ABD-3001	Advanced Biodesign	Phase 1	Active
Macrocyclic OMNI-EGFR Inhibitor	BlossomHill Therapeutics	Phase 1	Active
TUMORIN Clinical Trial	Nilogen Oncosystems	N/A (Diagnostic Validation)	Active
Membrex™	Metaclipse Therapeutics	Pre-clinical	Active
Lazertinib (Leclaza)	Genosco	Approved	Active
IPH5201 (anti-CD39 mAb)	Orega Biotech	Phase 2	Active
Platin-DRP®	Chosa Oncology	Validation	Active
Undisclosed RNA Immunotherapy	Epitopea	Pre-clinical	Active
Aspyre Clinical Test for Lung	Biofidelity	Commercial	Active
EGFR Mutation Detection Assay	Stilla Technologies	Assay Development/Validation	Active